aldesleukin

L03AC01

Forms & Strengths

Injectable powder for reconstitution: 22 million international units (IU) per vial

Adult Dosing

Metastatic renal cell carcinoma: 600,000 IU/kg (0.037 mg/kg) IV bolus every 8 hours for up to 14 doses
Repeat course: After 9 days of rest, administer a second course of up to 14 doses

Pediatric Dosing

Safety and efficacy in pediatric patients under 18 years have not been established

Indications

Mechanism of Action

Recombinant human interleukin-2 (IL-2) that binds to IL-2 receptors on lymphocytes
Enhances lymphocyte mitogenesis and cell-mediated cytotoxicity
Induces lymphokine-activated killer (LAK) cells and natural killer (NK) cell activity

Contraindications

Known hypersensitivity to interleukin-2 or any component of the formulation
Normal organ function impairment indicated by abnormal thallium stress test or pulmonary function tests
Organ allograft recipients
Untreated or active brain metastases
ECOG performance score >= 2

Adverse Reactions

Capillary leak syndrome (hypotension, edema, effusions)
Cardiovascular toxicity (arrhythmias, myocardial ischemia, tachycardia)
Central nervous system toxicity (confusion, somnolence, psychosis, coma)
Gastrointestinal toxicity (nausea, vomiting, diarrhea, GI bleeding)
Hematologic toxicity (anemia, thrombocytopenia, leukopenia)
Infection (increased risk of severe bacterial infections due to suppressed immunity)
Pulmonary toxicity (dyspnea, pulmonary congestion, pleural effusion)

Drug Interactions

Antihypertensive agents: May potentiate hypotension
Cardiotoxic, hepatotoxic, nephrotoxic, or myelotoxic agents: May increase cumulative toxicity
Corticosteroids and immunosuppressants: May antagonize the therapeutic efficacy of aldesleukin
Doxorubicin: Increased risk of cardiac toxicity

Curated Content: Needs Vetting Before Put to Clinical Use